| Literature DB >> 33145106 |
Anna Paczkowska1, Karolina Hoffmann2, Krzysztof Kus1, Dorota Kopciuch1, Tomasz Zaprutko1, Piotr Ratajczak1, Elżbieta Nowakowska1, Wiesław Bryl2.
Abstract
BACKGROUND: Scientific references lack sufficient amount of data on analyses of the reasons for hospital admissions or assessment of efficacy of arterial hypertension treatment at hospitals.Entities:
Year: 2020 PMID: 33145106 PMCID: PMC7596508 DOI: 10.1155/2020/3097198
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
General characteristics of hospitalized patients with arterial hypertension (n = 204).
| Group size | Total | 204 |
| Female | 62 | |
| Male | 142 | |
|
| ||
| Age (years) | Total | 56.77 ± 14.53 |
| Female | 59.74 ± 14.13 | |
| Male | 55 ± 14.56 | |
|
| ||
| Body mass index, BMI (kg/m2) | Total | 34.26 ± 8.02 |
| Female | 33.84 ± 7.86 | |
| Male | 34.45 ± 8.12 | |
|
| ||
| Duration of the disease (years) | Total | 11.06 ± 8.26 |
| Female | 11.49 ± 7.96 | |
| Male | 10.87 ± 8.41 | |
|
| ||
| Most common comorbidities | Obesity | 54.41% |
| Diabetes type 2 | 42.64% | |
| Angina pectoris | 12.25% | |
| Heart failure | 8.82% | |
| Brain stroke | 5.88% | |
(SD): average (standard deviation).
ICD classification of the patients admitted to the hospital due to hypertension (n = 204).
| Disease code and name |
| % |
|---|---|---|
| I10, Essential (primary) hypertension | 128 | 62.74 |
| I11.9, Hypertensive heart disease without heart failure | 48 | 23.53 |
| I15, Secondary hypertension-renovascular hypertension | 19 | 9.31 |
| I11, Hypertensive heart disease with heart failure | 8 | 3.92 |
| I12.9, Hypertensive chronic kidney disease without renal failure | 1 | 0.49 |
ICD: International Classification of Diseases.
Blood pressure values of the patients admitted to the hospital due to hypertension (n = 204).
| Blood pressure measurement | Systolic blood pressure values (mmHg) | Diastolic blood pressure values (mmHg) |
|---|---|---|
| Upon admission to the hospital | 168.92 ± 15.05 | 109.25 ± 14.47 |
| Upon discharge from the hospital | 128.00 ± 15.14 | 78.17 ± 10.32 |
| Daily average values (ABPM) | 128.54 ± 14.53 | 75.77 ± 8.64 |
ABPM: ambulatory blood pressure monitoring.
Hypertensive drugs used by the patients admitted to the hospital due to hypertension (n = 204).
| Hypertensive drugs group | Active substance | Percentage of patients receiving the drug (%) |
|---|---|---|
| Angiotensin-converting enzyme inhibitors (ACEI) | Overall | 61.27 |
| Ramipril | 25.98 | |
| Captopril | 19.11 | |
| Perindopril | 7.84 | |
| Verapamil | 2.45 | |
| Chinapril | 5.88 | |
|
| ||
|
| Overall | 69.30 |
| Bisoprolol | 28.92 | |
| Carvedilol | 16.17 | |
| Nebivolol | 16.17 | |
| Metoprolol | 8.33 | |
|
| ||
| Diuretics | Overall | 87.75 |
| Indapamid | 26.47 | |
| Furosemid | 5.39 | |
| Torasemid | 38.23 | |
| Spironolactone | 17.64 | |
|
| ||
| Calcium channel antagonist | Overall | 53.43 |
| Amlodipine | 45.58 | |
| Lercanidipine | 7.84 | |
|
| ||
| Angiotensin II receptor antagonists (ARBs) | Overall | 30.88 |
| Valsartan | 17.64 | |
| Telmisartan | 5.39 | |
| Losartan | 6.37 | |
| Candesartan | 1.47 | |
|
| ||
|
| Overall | 28.43 |
| Doxasosin | 23.52 | |
| Clonidine | 4.90 | |
|
| ||
| Fixed | Overall | 5.39 |
| Perindopril + amlodipine | 2.45 | |
| Valsartan + amlodipine | 1.96 | |
| Ramipril + amlodipine | 0.98 | |
Evaluation of efficacy of hypertension treatment in hospital environment according to the most common pharmacotherapy regimens.
| Pharmacotherapy regimen | Number of patients on the pharmacotherapy regimen | Blood pressure measurement upon admission to the hospital | Blood pressure measurement upon discharge from the hospital | Blood pressure control (<130/80 mmHg) % | ||
|---|---|---|---|---|---|---|
| Average systolic blood pressure values (mmHg, SEM ± SD) | Average diastolic blood pressure values (mmHg, SEM ± SD) | Average systolic blood pressure values (mmHg, SEM ± SD) | Average diastolic blood pressure values (mmHg, SEM ± SD) | |||
|
| 19 (9.3%) | 156.26 ± 12.04 | 94.37 ± 7.83 | 122.37 ± 9.06 | 73.63 ± 12.68 | 87.50 |
| Diuretics + ACEI (B) | 19 (9.3%) | 157.21 ± 9.46 | 92.68 ± 8.01 | 124.26 ± 9.42 | 76.79 ± 8.7 | 76.47 |
|
| 54 (26.47%) | 163.67 ± 14.12 | 94.61 ± 11.34 | 131.31 ± 12.30 | 79.43 ± 6.97 | 61.81 |
| ACEI + diuretics + ARBs (D) | 25 (12.25%) | 182.00 ± 23.06 | 103.32 ± 19.74 | 136.24 ± 16.25 | 82.80 ± 8.95 | 36.00 |
p: level of statistical significance; p < 0.05 was considered statistically significant. Statistically significant value in relation to group A for p < 0.05. #: statistically significant value in relation to group B for p < 0.05. &: statistically significant value in relation to group C for p < 0.05. ^: statistically significant value in relation to group D for p < 0.05. $: statistically significant value in relation to SBP reduction and DBP reduction among antihypertensive class combinations.